BioNexus Gene Lab (NASDAQ:BGLC) Stock Price Down 6.5% – Here’s Why

Posted by Alanna Baker on Sep 29th, 2026

BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report)’s share price dropped 6.5% on Monday. The company traded as low as $1.27 and last traded at $1.30. Approximately 11,408 shares were traded during mid-day trading, an increase of 198% from the average daily volume of 3,831 shares. The stock had previously closed at $1.39.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on BioNexus Gene Lab

BioNexus Gene Lab Price Performance

The stock has a market cap of $3.81 million, a PE ratio of -1.03 and a beta of 4.19. The company has a quick ratio of 5.28, a current ratio of 6.08 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $1.49 and its 200 day moving average is $1.93.

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter. BioNexus Gene Lab had a negative return on equity of 32.92% and a negative net margin of 82.38%.The business had revenue of $0.08 million for the quarter.

BioNexus Gene Lab Company Profile

(Get Free Report)

BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a biotechnology and molecular diagnostics company focused on developing genetic tests intended to support the early detection of cancer and other diseases. Its diagnostic work uses blood-based and molecular analysis to identify biological indicators that may help healthcare providers assess disease risk and guide further evaluation.

The company operates through two primary business areas: Molecular Diagnostics and Chemical Trading. The Molecular Diagnostics segment develops and commercializes genetic testing products, while the Chemical Trading segment distributes industrial chemicals and related products to customers in its served markets.

BioNexus Gene Lab is headquartered in Kuala Lumpur, Malaysia, and its operations have included activities in the Malaysian market.